News

Willdan Group's Third Quarter Earnings Showcase Strong Growth

Willdan Group's Third Quarter Earnings Showcase Strong Growth

Willdan Group Reports Third Quarter 2024 Results

Willdan Group, Inc. (NASDAQ: WLDN) is excited to share its financial results for the third quarter, highlighting a period of remarkable growth and strategic movement that distinguishes the company in the competitive consulting sector.

Third Quarter 2024 Highlights

During the third quarter of 2024, Willdan Group achieved:

  • Contract revenue reaching $158.3 million, reflecting a substantial 19.2% increase.
  • Net revenue of $75.7 million, an admirable growth of 15.9%.
  • Net income surged to $7.3 million, a significant jump from $1.6 million in the previous year.
  • Adjusted EBITDA at $15.2 million, demonstrating an impressive rise of 49.7% year-over-year.
  • GAAP diluted EPS climbed to $0.51, compared to $0.11 previously.
  • Adjusted diluted EPS also advanced to $0.73 from $0.37.

Executive Management Insights

Mike Bieber, President and CEO of Willdan, expressed strong optimism regarding their quarterly performance. "Our results surpassed analysts' expectations across all metrics. The growing emphasis on electrification drives the demand for our energy transition services. Our consulting capabilities are allowing us to better navigate complex funding landscapes to fulfill client objectives effectively. We are also cross-selling services more successfully than ever before. In a strategic move, we recently purchased Enica Engineering, enhancing our offerings in the commercial market, particularly in pharmaceuticals, healthcare, and research. As we build on this success, we've raised our financial targets for the lat year of 2024," said Bieber.

Nine Months Year-to-Date 2024 Overview

For the nine months leading up to September 27, Willdan also demonstrated solid financial performance:

  • Total contract revenue for the period hit $421.7 million, marking a 19.0% increase.
  • Net revenue recorded was $217.1 million, a 14.9% growth compared to the same timeframe last year.
  • Net income reached $14.9 million, a sharp rise from $2.9 million.
  • Adjusted EBITDA stood at $39.1 million, up 38.3% year-over-year.
  • GAAP diluted EPS rose to $1.05 from $0.21, further illustrating the company's growth trajectory.
  • Adjusted diluted EPS showed significant improvement, increasing to $1.70 from $0.95.

Fiscal Year 2024 Financial Targets Revised

Anticipating strong momentum, Willdan Group revised its financial expectations for fiscal year 2024:

  • Net revenue anticipated to be between $285 million and $295 million.
  • Adjusted EBITDA forecasted in the range of $52 million to $54 million.
  • Adjusted diluted EPS is expected to fall between $2.15 and $2.25 per share.

Investment Procedures and Growth Strategy

These projections are built upon the assumption of 14.2 million diluted shares and an effective tax rate of 14%, excluding the potential for future acquisitions. Willdan’s strong fundamentals coupled with its strategic acquisitions position the company for enhanced growth in the rapidly evolving energy consultancy market.

Third Quarter 2024 Conference Call

Willdan will host a conference call to discuss its third quarter financial results. Participants can join at 5:30 p.m. Eastern / 2:30 p.m. Pacific. The call can be accessed by dialling 877-407-2988 (or 201-389-0923). The call will also be available via webcast on Willdan's website.

About Willdan Group, Inc.

Willdan Group, Inc. is a nationwide leader in providing professional and consulting services to private industry, government agencies, and utility clients across a wide range of sectors. Their services span energy efficiency, municipal planning, engineering, and financial consulting, ensuring a comprehensive approach to modern challenges.

Frequently Asked Questions

What were Willdan Group's key financial highlights for Q3 2024?

Willdan reported a 19.2% increase in contract revenue, reaching $158.3 million, alongside a net income rise to $7.3 million.

What influenced the growth in Willdan's revenue?

The demand for energy transition services associated with electrification has significantly boosted revenue, as noted by the CEO.

How did Willdan's nine months performance compare year-over-year?

In the first nine months of 2024, Willdan achieved a 19.0% increase in contract revenue to $421.7 million, and a significant rise in net income.

What are Willdan's updated financial targets for FY 2024?

Willdan expects between $285 million to $295 million in net revenue and adjusted EBITDA of $52 million to $54 million for FY 2024.

Who is Willdan Group, Inc.?

Willdan Group, Inc. is a consulting firm specializing in energy efficiency, engineering, and financial consulting services for utilities and government agencies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading